Benign prostatic hyperplasia: current clinical practice

Benign prostatic hyperplasia (BPH) is the most common benign adenoma in men, affecting nearly all of them. BPH represents a clinically significant cause of bladder outflow obstruction in up to 40% of men. The growing frequency of diagnosis is due to increasing life expectancy and a trend toward seek...

Full description

Saved in:
Bibliographic Details
Published inPrimary care Vol. 37; no. 3; p. 583
Main Authors Djavan, Bob, Eckersberger, Elisabeth, Finkelstein, Julia, Espinosa, Geovanni, Sadri, Helen, Brandner, Roland, Shah, Ojas, Lepor, Herbert
Format Journal Article
LanguageEnglish
Published United States 01.09.2010
Subjects
5-alpha Reductase Inhibitors - therapeutic use
Adrenergic alpha-Antagonists - therapeutic use
Cholinergic Antagonists - therapeutic use
Dihydrotestosterone - metabolism
Disease Progression
Humans
Male
Primary Health Care
Prostatic Hyperplasia - therapy
Randomized Controlled Trials as Topic
Surveys and Questionnaires
Testosterone - metabolism
Watchful Waiting
Online AccessGet more information

Cover

More Information
Summary:Benign prostatic hyperplasia (BPH) is the most common benign adenoma in men, affecting nearly all of them. BPH represents a clinically significant cause of bladder outflow obstruction in up to 40% of men. The growing frequency of diagnosis is due to increasing life expectancy and a trend toward seeking medical advice at earlier stages of the disease. The last decade has witnessed a significant shift in emphasis in the management of BPH, with medical therapies and, to a lesser extent, minimally invasive therapies becoming the predominant active therapy choices. The development of effective therapies such as alpha-adrenergic blockers and 5-alpha-reductase inhibitors and the possibility of their combined use represent the most significant advance in the treatment of BPH.
ISSN:1558-299X
DOI:10.1016/j.pop.2010.04.004